Sameer K Nath1, James B Yu2, Lynn D Wilson3. 1. Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT. 2. Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT; Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT. 3. Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT; Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT. Electronic address: Lynn.wilson@yale.edu.
Abstract
BACKGROUND: The aims of this study were: (1) to determine whether AA patients with MF have a worse prognosis despite accounting for varying clinical factors at presentation, and (2) to assess whether a racial disparity exists regarding utilization of radiation therapy (RT) as an initial treatment modality. MATERIALS AND METHODS: The SEER 1988-2008 public use database was investigated. Univariate and multivariate analysis was used to assess for factors significantly associated with disease-specific survival (DSS), overall survival (OS), and RT utilization survival. RESULTS: A total of 4892 patients with MF were identified with a median follow-up of 58 months. On multivariate analysis including tumor registry, age, sex, marital status, and tumor stage, AA race was significantly correlated with a worse OS (hazard ratio [HR], 1.58; P < .001) and DSS (HR, 1.78; P < .001). With regard to RT utilization, more advanced age (odds ratio [OR], 1.005; P < .001) and higher stage (OR, 3.03; P < .001) were associated with a higher likelihood of receiving RT, whereas female sex (OR, 0.81; P = .03) was associated with a lower likelihood of receiving RT. AA race was not significantly associated with RT utilization (P = .58). CONCLUSION: AA race was associated with poorer survival despite accounting for demographic factors and tumor stage. Differences in RT utilization according to AA race were not found, however RT was less utilized for female patients. The etiology of this poorer prognosis is unclear and might be related to access to medical care, socioeconomic factors, or undetermined biological differences.
BACKGROUND: The aims of this study were: (1) to determine whether AA patients with MF have a worse prognosis despite accounting for varying clinical factors at presentation, and (2) to assess whether a racial disparity exists regarding utilization of radiation therapy (RT) as an initial treatment modality. MATERIALS AND METHODS: The SEER 1988-2008 public use database was investigated. Univariate and multivariate analysis was used to assess for factors significantly associated with disease-specific survival (DSS), overall survival (OS), and RT utilization survival. RESULTS: A total of 4892 patients with MF were identified with a median follow-up of 58 months. On multivariate analysis including tumor registry, age, sex, marital status, and tumor stage, AA race was significantly correlated with a worse OS (hazard ratio [HR], 1.58; P < .001) and DSS (HR, 1.78; P < .001). With regard to RT utilization, more advanced age (odds ratio [OR], 1.005; P < .001) and higher stage (OR, 3.03; P < .001) were associated with a higher likelihood of receiving RT, whereas female sex (OR, 0.81; P = .03) was associated with a lower likelihood of receiving RT. AA race was not significantly associated with RT utilization (P = .58). CONCLUSION: AA race was associated with poorer survival despite accounting for demographic factors and tumor stage. Differences in RT utilization according to AA race were not found, however RT was less utilized for female patients. The etiology of this poorer prognosis is unclear and might be related to access to medical care, socioeconomic factors, or undetermined biological differences.
Authors: Thatcher R Heumann; Natia Esiashvili; Sareeta Parker; Jeffrey M Switchenko; Anees Dhabbaan; Michael Goodman; Mary Jo Lechowicz; Christopher R Flowers; Mohammad K Khan Journal: Int J Radiat Oncol Biol Phys Date: 2015-02-07 Impact factor: 7.038
Authors: Pamela B Allen; Subir Goyal; Tim Niyogusaba; Colin O'Leary; Amy Ayers; Erica S Tarabadkar; Mohammad K Khan; Mary Jo Lechowicz Journal: JAMA Dermatol Date: 2022-09-07 Impact factor: 11.816
Authors: Shiun Chang; Lucia Seminario-Vidal; Kenneth Y Tsai; Pei-Ling Chen; Xiaofei Song; Alvaro de Mingo Pulido; Leticia Tordesillas; Xingzhi Song; Rhianna A Reed; Andrea Harkins; Shannen Whiddon; Jonathan V Nguyen; Carlos Moran Segura; Chaomei Zhang; Sean Yoder; Zena Sayegh; Yun Zhao; Jane L Messina; Carly M Harro; Xiaohui Zhang; José R Conejo-Garcia; Anders Berglund; Lubomir Sokol; Jianhua Zhang; Paulo C Rodriguez; James J Mulé; Andrew P Futreal Journal: Cancer Discov Date: 2022-05-02 Impact factor: 38.272
Authors: Shamir Geller; Emily Lebowitz; Melissa P Pulitzer; Steven M Horwitz; Alison J Moskowitz; Steve Dusza; Patricia L Myskowski Journal: J Am Acad Dermatol Date: 2019-09-06 Impact factor: 11.527
Authors: Xochiquetzal U Martinez; Arnab Chowdhury; Tracey Stiller; Joycelynne Palmer; Matthew Loscalzo; Estella Barrios; Farah R Abdulla; Jasmine Zain; Steven T Rosen; Christiane Querfeld Journal: Support Care Cancer Date: 2021-05-07 Impact factor: 3.603
Authors: Ivan V Litvinov; Michael T Tetzlaff; Elham Rahme; Michelle A Jennings; David R Risser; Pamela Gangar; Elena Netchiporouk; Linda Moreau; Victor G Prieto; Denis Sasseville; Madeleine Duvic Journal: Cancer Med Date: 2015-07-01 Impact factor: 4.452